The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.

ABSTRACT: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a unique class of oral anti-hyperglycaemic medications that act to reduce glucose reabsorption in the renal proximal tubules, thereby enhancing urinary glucose excretion. Large randomized placebo-controlled trials in people with diabetes at high cardiovascular risk have demonstrated that SGLT2 inhibitors reduce heart failure hospitalization within months of commencing therapy. These findings are of considerable interest, as diabetes is associated with an increased risk of both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. In addition, left ventricular (LV) hypertrophy and impaired diastolic function is thought to be more prevalent in people with diabetes. Although many hypotheses have b

SUBMITTER: Lan NSR 

PROVIDER: S-EPMC6816235 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature